Dashboard
1
Flat results in Mar 26
- OPERATING CASH FLOW(Y) Lowest at CNY 779.01 MM
- ROCE(HY) Lowest at 9.39%
2
With ROE of 10.33%, it has a fair valuation with a 1.47 Price to Book Value
3
Majority shareholders : FIIs
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,671 Million (Mid Cap)
18.00
NA
2.19%
-0.45
10.33%
1.52
Revenue and Profits:
Net Sales:
406 Million
(Quarterly Results - Jun 2026)
Net Profit:
88 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.97%
0%
-7.97%
6 Months
-26.64%
0%
-26.64%
1 Year
-38.76%
0%
-38.76%
2 Years
-23.24%
0%
-23.24%
3 Years
-60.67%
0%
-60.67%
4 Years
-72.6%
0%
-72.6%
5 Years
-87.16%
0%
-87.16%
Ovctek China, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.82%
EBIT Growth (5y)
0.57%
EBIT to Interest (avg)
64.57
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.37
Tax Ratio
15.50%
Dividend Payout Ratio
35.10%
Pledged Shares
0
Institutional Holding
0.06%
ROCE (avg)
33.21%
ROE (avg)
19.66%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
1.83
EV to EBIT
13.11
EV to EBITDA
10.30
EV to Capital Employed
2.52
EV to Sales
3.79
PEG Ratio
NA
Dividend Yield
1.81%
ROCE (Latest)
19.24%
ROE (Latest)
10.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.06%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
405.80
392.50
3.39%
Operating Profit (PBDIT) excl Other Income
127.70
144.40
-11.57%
Interest
2.00
3.80
-47.37%
Exceptional Items
12.90
6.40
101.56%
Consolidate Net Profit
87.80
102.20
-14.09%
Operating Profit Margin (Excl OI)
202.40%
253.50%
-5.11%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 3.39% vs -6.26% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -14.09% vs -29.71% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,849.80
1,801.60
2.68%
Operating Profit (PBDIT) excl Other Income
812.90
835.20
-2.67%
Interest
16.70
15.60
7.05%
Exceptional Items
-57.60
-33.40
-72.46%
Consolidate Net Profit
543.90
621.80
-12.53%
Operating Profit Margin (Excl OI)
336.80%
375.60%
-3.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.68% vs 4.39% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -12.53% vs -14.71% in Dec 2024
About Ovctek China, Inc. 
Ovctek China, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






